Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, et al.
Frontiers in Public Health (2018) Vol. 6
Open Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future
Olayinka O. Ogunleye, Debashis Basu, Debjani Mueller, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 191
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries
Brian Godman, Abiodun Egwuenu, Mainul Haque, et al.
Life (2021) Vol. 11, Iss. 6, pp. 528-528
Open Access | Times Cited: 179
Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future
Brian Godman, Mainul Haque, Judy McKimm, et al.
Current Medical Research and Opinion (2019) Vol. 36, Iss. 2, pp. 301-327
Open Access | Times Cited: 139
Medicine Shortages: Gaps Between Countries and Global Perspectives
Ángela Acosta, Egdda Patricia Vanegas, Joan Rovira, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 117
Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future
Brian Godman, Debashis Basu, Yogan Pillay, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 112
Artificial Intelligence and Health Technology Assessment: Anticipating a New Level of Complexity
Hassane Alami, Pascale Lehoux, Yannick Auclair, et al.
Journal of Medical Internet Research (2020) Vol. 22, Iss. 7, pp. e17707-e17707
Open Access | Times Cited: 106
Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future
Brian Godman, Mainul Haque, Salequl Islam, et al.
Frontiers in Public Health (2020) Vol. 8
Open Access | Times Cited: 103
Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries
Brian Godman, Holly McCabe, Trudy Leong, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2020) Vol. 20, Iss. 1, pp. 1-26
Open Access | Times Cited: 69
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Brian Godman, Andrew Hill, Steven Simoens, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2021) Vol. 21, Iss. 4, pp. 527-540
Open Access | Times Cited: 63
Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications
Zikria Saleem, Brian Godman, Faiza Azhar, et al.
Expert Review of Anti-infective Therapy (2021) Vol. 20, Iss. 1, pp. 71-93
Open Access | Times Cited: 63
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
Sabine Vogler, Peter A. Schneider, Martin Zuba, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 63
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Evelien Moorkens, Brian Godman, Isabelle Huys, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 56
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes
Priya Vart, Muthiah Vaduganathan, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 12, pp. 1754-1762
Open Access | Times Cited: 40
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
Karel H. van der Pol, Mohamad Aljofan, Olivier Blin, et al.
Applied Health Economics and Health Policy (2023) Vol. 21, Iss. 6, pp. 831-840
Open Access | Times Cited: 23
Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review
Kristina Medlinskiene, Justine Tomlinson, Iuri Marques, et al.
BMC Health Services Research (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 46
The Evolution of Personalized Healthcare and the Pivotal Role of European Regions in its Implementation
Christine Nardini, Venet Osmani, Paola Giulia Cormio, et al.
Personalized Medicine (2021) Vol. 18, Iss. 3, pp. 283-294
Open Access | Times Cited: 42
Advances in microalgal cell wall polysaccharides: a review focused on structure, production, and biological application
Guilherme Augusto Colusse, Jaqueline Carneiro, Maria Eugênia R. Duarte, et al.
Critical Reviews in Biotechnology (2021), pp. 1-16
Closed Access | Times Cited: 40
Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model
David Z.I. Cherney, Aleksandra Drzewiecka‐Antonik, Kerstin Folkerts, et al.
Journal of Medical Economics (2025), pp. 1-19
Open Access
Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities
F. Dehle, Kevin Phan, Nicholas Higgins, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2025)
Closed Access
Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future
Brian Godman, Debashis Basu, Yogan Pillay, et al.
Hospital Practice (2020) Vol. 48, Iss. 2, pp. 51-67
Open Access | Times Cited: 47
Integrative Review of Managed Entry Agreements: Chances and Limitations
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, et al.
PharmacoEconomics (2020) Vol. 38, Iss. 11, pp. 1165-1185
Open Access | Times Cited: 45
Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries
Brian Godman, Christoffel Grobler, Marianne Van-De-Lisle, et al.
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 18, pp. 2237-2255
Open Access | Times Cited: 44
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Brian Godman, Andrew Hill, Steven Simoens, et al.
Generics and Biosimilars Initiative Journal (2019) Vol. 8, Iss. 2, pp. 49-70
Open Access | Times Cited: 43
Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications
Mainul Haque, Santosh Kumar, Jaykaran Charan, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 38
Deep learning for early detection of pathological changes in X-ray bone microstructures: case of osteoarthritis
Livija Jakaite, Vitaly Schetinin, Jiřı́ Hladůvka, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top